Armistice Capital’s Cytokinetics CYTK Stock Holding History

Armistice Capital’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$130M	Sell	1,530,000 -170,000	-10%	-$12.2M	1.59%	4
2026 Q1	$112M	Buy	1,700,000 +200,000	+13%	+$12.7M	1.99%	6
2025 Q4	$95.3M	Buy	1,500,000 +550,000	+58%	+$34.2M	1.13%	10
2025 Q3	$52.2M	Sell	950,000 -390,000	-29%	-$16.1M	0.77%	19
2025 Q2	$44.3M	Sell	1,340,000 -1,360,000	-50%	-$47.3M	0.76%	16
2025 Q1	$109M	Buy	2,700,000 +2,090,000	+343%	+$96M	1.63%	7
2024 Q4	$28.7M	Sell	610,000 -1,590,000	-72%	-$82.6M	0.39%	52
2024 Q3	$116M	Buy	2,200,000 +1,200,000	+120%	+$66.9M	1.86%	6
2024 Q2	$54.2M	Buy	1,000,000 +300,000	+43%	+$18.1M	0.68%	20
2024 Q1	$49.1M	Buy	+700,000	New	+$54.1M	0.65%	21

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Armistice Capital's CYTK Position: Q2 2026 in Review

Armistice Capital increased its Cytokinetics (CYTK) stake by 57% in Q2 2026, buying an estimated $31.4M and bringing the position to 1,201,342 shares worth $102M. The position accounts for 1.25% of the portfolio, ranked #7.

Armistice Capital first reported a position in CYTK in Q1 2024 and has held it in 10 quarters since. The position peaked at $112M in Q2 2024. 483 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Armistice Capital held 1,201,342 shares of Cytokinetics worth $102M as of Q2 2026.
Armistice Capital bought 436,804 Cytokinetics shares in Q2 2026, an estimated $31.4M.
Cytokinetics made up 1.25% of Armistice Capital's portfolio in Q2 2026, its #7 holding.
Armistice Capital first reported a position in Cytokinetics in Q1 2024 and has held it in 10 quarters since.
Armistice Capital's Cytokinetics position peaked at $112M in Q2 2024.
483 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.